New research has found that extra abdominal fat is strongly associated with an increased risk of heart failure. Excess belly ...

A melanocortin-4 receptor agonist did not induce significant decreases in BMI for patients with four rare genetic forms of obesity, according to topline results from four substudies of a phase 3 trial ...

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

More U.S. students are gaining weight, obesity is rising, but fewer are taking action to improve their health and build better daily habits.

Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.

The Phase 3 EMANATE study is a basket trial looking at the efficacy of Rhythm Pharmaceuticals’ injectable obesity drug across ...

Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching with an upcoming FDA decision, a few other potential areas of expansio | The ...

New research suggests that measures of excess weight around the waist (central obesity or visceral fat) may increase the risk ...

Researchers show that pharmacological activation of hypoxia signaling improves metabolism, limits fat accumulation, and ...

A new national study has placed a spotlight on weight and health across the United States, and the numbers are stark.

Excess belly weight or visceral fat may be a stronger predictor of heart failure than BMI, and inflammation plays a major role, according to a new study.

Augusta seems to have a weight problem with WalletHub ranking it among the most fat cities in the nation. Here's why.